Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

The pharmaceutical giant also issued fiscal 2025 profit guidance ... said demand for its weight loss and diabetes drugs would not meet its lofty expectations. Notably, Eli Lilly said it plans ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Analysts had expected profit of $4.52 billion ... the Danish company behind weight-loss drugs Ozempic and Wegovy, topped estimates in its fourth-quarter report. Eli Lilly shares were up roughly ...

The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug ...

Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates ... Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound grew to $3. ...